{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:51:18Z","timestamp":1793839878998,"version":"4.6.1"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2022,4,1]]},"DOI":"10.1001\/jamaoncol.2021.7366","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T16:01:46Z","timestamp":1645113706000},"page":"553","source":"Crossref","is-referenced-by-count":52,"title":["Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy"],"prefix":"10.1001","volume":"8","author":[{"given":"Guo-Ying","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of NPC Diagnosis and Therapy, Guangzhou, China"},{"name":"Department of Radiotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang-Zhong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of NPC Diagnosis and Therapy, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Shen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of NPC Diagnosis and Therapy, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of NPC Diagnosis and Therapy, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of NPC Diagnosis and Therapy, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Fang","family":"Ye","sequence":"additional","affiliation":[{"name":"Clinical Research Design Division, Sun Yat-sen Memorial Hospital, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of NPC Diagnosis and Therapy, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang-Ru","family":"Ke","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of NPC Diagnosis and Therapy, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Hui","family":"Lv","sequence":"additional","affiliation":[{"name":"Medical Affairs Office, The Fifth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nian","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of NPC Diagnosis and Therapy, Guangzhou, China"},{"name":"Department of Medical Imaging, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of NPC Diagnosis and Therapy, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Xin","family":"Bei","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of NPC Diagnosis and Therapy, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo-Chen","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of NPC Diagnosis and Therapy, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of NPC Diagnosis and Therapy, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Xiong","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of NPC Diagnosis and Therapy, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of NPC Diagnosis and Therapy, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Xiong","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of NPC Diagnosis and Therapy, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Qun","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of NPC Diagnosis and Therapy, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10192","key":"coi210104r1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma.","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"coi210104r2","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3322\/caac.v70.4","article-title":"Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"70","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"27","key":"coi210104r3","doi-asserted-by":"publisher","first-page":"24511","DOI":"10.18632\/oncotarget.v6i27","article-title":"Distant metastasis risk and patterns of nasopharyngeal carcinoma in the era of IMRT: long-term results and benefits of chemotherapy.","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"issue":"11","key":"coi210104r4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41571-021-00524-x","article-title":"Nasopharyngeal carcinoma: an evolving paradigm.","volume":"18","author":"Wong","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"coi210104r7","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s00432-012-1219-x","article-title":"Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma.","volume":"138","author":"Jin","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"coi210104r8","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.oraloncology.2007.06.004","article-title":"Retrospective case series of gemcitabine plus cisplatin in the treatment of recurrent and metastatic nasopharyngeal carcinoma.","volume":"44","author":"Wang","year":"2008","journal-title":"Oral Oncol"},{"issue":"10054","key":"coi210104r9","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/S0140-6736(16)31388-5","article-title":"Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.","volume":"388","author":"Zhang","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"coi210104r10","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrclinonc.2010.82","article-title":"Metronomic chemotherapy: new rationale for new directions.","volume":"7","author":"Pasquier","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"coi210104r11","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"coi210104r12","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1093\/annonc\/mdw101","article-title":"Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.","volume":"27","author":"Luo","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"coi210104r13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jama.2020.23370","article-title":"Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial.","volume":"325","author":"Wang","year":"2021","journal-title":"JAMA"},{"issue":"10297","key":"coi210104r14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(21)01123-5","article-title":"Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.","volume":"398","author":"Chen","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"coi210104r15","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/jjco\/hyn022","article-title":"Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer.","volume":"38","author":"Chua","year":"2008","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"coi210104r16","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00280-007-0641-2","article-title":"Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma.","volume":"62","author":"Li","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"coi210104r17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1517\/14656566.2014.866652","article-title":"Treatment outcome of docetaxel, capecitabine and cisplatin regimen for patients with refractory and relapsed nasopharyngeal carcinoma who failed previous platinum-based chemotherapy.","volume":"15","author":"Gao","year":"2014","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"coi210104r18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"12","key":"coi210104r20","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1038\/sj.bjc.6690627","article-title":"Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study.","volume":"80","author":"Hong","year":"1999","journal-title":"Br J Cancer"},{"key":"coi210104r21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40880-016-0103-5","article-title":"A new prognostic histopathologic classification of nasopharyngeal carcinoma.","volume":"35","author":"Wang","year":"2016","journal-title":"Chin J Cancer"},{"issue":"1","key":"coi210104r22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/cac2.v40.1","article-title":"The role of capecitabine as maintenance therapy in de novo metastatic nasopharyngeal carcinoma: a propensity score matching study.","volume":"40","author":"Sun","year":"2020","journal-title":"Cancer Commun (Lond)"},{"key":"coi210104r23","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.2147\/CMAR","article-title":"Oral maintenance chemotherapy using S-1\/capecitabine in metastatic nasopharyngeal carcinoma patients after systemic chemotherapy: a single-institution experience.","volume":"12","author":"Guo","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"22","key":"coi210104r24","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy.","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"issue":"15","key":"coi210104r25","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.1158\/1078-0432.CCR-05-0437","article-title":"Maintenance therapy to suppress micrometastasis: the new challenge for adjuvant cancer treatment.","volume":"11","author":"Epstein","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"26","key":"coi210104r26","doi-asserted-by":"publisher","first-page":"E5226","DOI":"10.1073\/pnas.1705066114","article-title":"Maintenance of antiangiogenic and antitumor effects by orally active low-dose capecitabine for long-term cancer therapy.","volume":"114","author":"Zhang","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"coi210104r27","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial.","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"coi210104r28","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","article-title":"Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial.","volume":"27","author":"Mai","year":"2021","journal-title":"Nat Med"},{"issue":"17","key":"coi210104r29","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1002\/cncr.v127.17","article-title":"Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study.","volume":"127","author":"Ruan","year":"2021","journal-title":"Cancer"},{"key":"coi210104r30","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw525.48","article-title":"KEYNOTE-122: phase 2 study of pembrolizumab versus standard-of-care chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal carcinoma.","volume":"114","author":"Ng","year":"2016","journal-title":"Ann Oncol."},{"key":"coi210104r31","doi-asserted-by":"publisher","first-page":"S786","DOI":"10.1016\/j.annonc.2021.08.1268","article-title":"858O Results of KEYNOTE-122: a phase III study of pembrolizumab (pembro) monotherapy vs chemotherapy (chemo) for platinum-pretreated, recurrent or metastatic (R\/M) nasopharyngeal carcinoma (NPC).","volume":"32","author":"Chan","year":"2021","journal-title":"Ann Oncol"},{"issue":"17","key":"coi210104r32","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.","volume":"357","author":"Vermorken","year":"2007","journal-title":"N Engl J Med"},{"issue":"17","key":"coi210104r33","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa070956","article-title":"Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.","volume":"357","author":"Posner","year":"2007","journal-title":"N Engl J Med"},{"issue":"34","key":"coi210104r34","doi-asserted-by":"publisher","first-page":"8636","DOI":"10.1200\/JCO.2004.00.1990","article-title":"Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.","volume":"23","author":"Hitt","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"coi210104r35","doi-asserted-by":"publisher","first-page":"201","DOI":"10.21037\/atm","article-title":"The efficacy of first-line chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis.","volume":"6","author":"Ma","year":"2018","journal-title":"Ann Transl Med"},{"issue":"4","key":"coi210104r36","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00432-009-0682-5","article-title":"Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer.","volume":"136","author":"Li","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"coi210104r37","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/S1470-2045(13)70154-2","article-title":"Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.","volume":"14","author":"Cunningham","year":"2013","journal-title":"Lancet Oncol"},{"issue":"31","key":"coi210104r38","doi-asserted-by":"publisher","first-page":"5248","DOI":"10.1200\/JCO.2009.21.9733","article-title":"Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer.","volume":"27","author":"Lee","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi210104r39","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1200\/JCO.2013.50.5669","article-title":"Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.","volume":"32","author":"Vergote","year":"2014","journal-title":"J Clin Oncol"},{"issue":"33","key":"coi210104r40","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1200\/JCO.2013.53.3570","article-title":"Tamibarotene as maintenance therapy for acute promyelocytic leukemia: results from a randomized controlled trial.","volume":"32","author":"Shinagawa","year":"2014","journal-title":"J Clin Oncol"},{"key":"coi210104r5","unstructured":"National Comprehensive Cancer Network. Head and neck cancers, version 1.2015. Accessed May 12, 2015. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/head-and-neck.pdf.2015"},{"key":"coi210104r6","unstructured":"National Comprehensive Cancer Network. Head and neck cancers, version 3.2021. April 27, 2021. Accessed June 23, 2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/head-and-neck.pdf"},{"key":"coi210104r19","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events. Accessed June 14, 2010. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2789163\/jamaoncology_liu_2022_oi_210104_1650482097.72288.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T15:23:06Z","timestamp":1650554586000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2789163"}},"subtitle":["A Phase 3 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2021.7366","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,1]]}}}